Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Update: Montebello to distribute Biohit products in Norway


Posted on: 23 Feb 18

Biohit Oyj Press release, February 23rd, 2018 at 10:00 a.m. local time (EET)

Biohit Oyj and Montebello Diagnostics AS have signed an agreement for the distribution of Biohit diagnostic products in Norway. The contract has been signed for three years with a continuation option.

Managing Director Mika Søderberg, Montebello Diagnostics AS: “The Biohit product range will significantly strengthen our portfolio of gastrointestinal tract diagnostics. GastroPanel® innovation is welcome to the Norwegian health care to promote safe and cost-effective diagnosis and screening of dyspepsia as well as Helicobacter pylori-associated and autoimmune type atrophic gastritis with related risks of e.g. gastric cancer.”

CEO Semi Korpela, Biohit Oyj: ”With this agreement, Montebello obtains the rights to distribute Biohit diagnostic products in Norway. Implementation of GastroPanel in health care is also facilitated by the fact that Montebello has during the past several years, delivered to domestic laboratories numerous analytical instruments suitable e.g. for running of GastroPanel-ELISA-tests, all exploiting the microplate vertical measurement technology widely used as a global standard (1 - 5).”

Additional information: 
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com

  1. www.biohithealthcare.com/additional-information
  2. www.biohithealthcare.com Rationale of the Biohit GI Panel
  3. http://www.biohithealthcare.com/limitations-of-helicobacter-pylori-diagnostics
  4. Syrjänen K. Caveats in diagnosis of Helicobacter pylori infection can be avoided by a panel of serum biomarkers (GastroPanel®). J Carcinog Mutagen 2017;7(6), e123. doi:10.4172/2157-2518.1000e123
  5. http://www.gastropanel.com/decision-makers/screening-model

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com

Montebello in brief

Montebello Diagnostics AS is a well-known Norwegian distributor of diagnostic kits within microbiology in Norway with 20+ years of operations. Montebello is privately held with headquarters in Oslo, Norway. Montebello is currently expanding into new business areas and building their existing business further. www.montebello.no

GlobeNewswire
globenewswire.com

Last updated on: 26/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.